^
Association details:
Biomarker:PALB2 mutation
Cancer:Ovarian Cancer
Drug:Lynparza (olaparib) (PARP inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: B - Late Trials
Source:
Title:

740P - Olaparib maintenance monotherapy for non-germline BRCA1/2-mutated (non-gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC): Exploratory biomarker analyses of the phase IIIb OPINION study

Published date:
09/13/2021
Excerpt:
279 pts were enrolled and received olaparib maintenance (tablets; 300 mg bid)....12% of pts (34/279) had a non-BRCA HRRm (8 RAD51C; 7 BRIP1; 7 RAD51D; 3 CDK12; 2 FANCL; 2 PALB2; 1 ATM; 1 BARD1; 1 RAD51B; 1 CHEK2 and RAD51D; 1 PPP2R2A and RAD51C).....Pts with a non-BRCA HRRm achieved longer PFS benefit compared with the non HRRm subgroup.
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

Excerpt:
...Difference in levels of PAR or PARP-1 before and after study treatment`Mutations in BRCA1/2, RAD51B, RAD51C, RAD51D, PPM1D, FANCM, BRIP1, PALB2 and BARD1 in germline tissue compared to tumor tissue...
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

A study, performed in several centers, to examine the treatment of Olaparib at the time of disease progression in ovarian, peritoneal or fallopian tube cancer before an operation.

Excerpt:
...• Biological effects in the primary tumour following a short pre-operative course of treatment with Olaparib in patients with platinum sensitive relapsed ovarian cancer; the biological effects are assess in terms of the degree of PAR or PARP-1 inhibition (in tissue and ctDNA) • Germline HRD mutations and tissue mutation with respect to BRCA1/2, RAD51B, RAD51C, RAD51D, PPM1D, FANCM, BRIP1, PALB2 and BARD1 (in tissue and ctDNA)• Generate initial clinical efficacy data for future studies (RECIST 1.1)...